Novartis in July became the latest pharmaceutical company to shut down its antibiotics research projects.
The move comes as FDA commissioner Scott Gottlieb has expressed concern over the growing epidemic around antimicrobial resistance, which is when bacteria grow resistant to available medications.
New options to combat the resistant bacteria include antibiotic-combination therapy and bacteriophage therapy.
Just two years after Novartis announced it would embrace the challenge of searching for cures for life-threatening infections known as superbugs, the drugmaker said last week it would exit antibacterial and antiviral research.
Novartis’ retreat follows a growing trend of big pharmaceutical companies — including AstraZeneca, Sanofi, and Allergan — that are exiting from this type of research because of a lack of profit.See the rest of the story at Business Insider
NOW WATCH: How NASA saved the world
Meet the 29-year-old who founded a company that’s using technology to find treatments for diseases thought to be incurableA facility giving marijuana to people with addiction has had a major shakeup after it felt ‘like walking into a cloud of smoke’Meet the 30 healthcare leaders under 40 who are using technology to shape the future of medicine
Best Clickbank Products